Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Nicole Lamanna, Marco Montilo, Árpád Illés, Gabriel Etienne, Julio Delgado, Bryone Kuss, Constantine Tam, Fritz Offner, Francesco Bosch, Matthew S. Davids, Ulrich Jager, Paolo Ghia, Florence Cymalista, David T. Weaver, Stephanie Lustgarten, Hagop Youssoufian, Stephan Stilgenbauer, Ian W. Flinn

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) after 2 prior therapies. In the phase 3 DUO trial, duvelisib 25 mg twice daily (BID) significantly improved efficacy vs ofatumumab (median progression-free survival [PFS], 13.3 vs 9.9 months; HR, 0.52 [P < .0001]; overall response rate, 74% vs 45% [P < .0001]) in patients with R/R CLL/SLL.1 Treatment-emergent adverse events (TEAEs) of special interest (AESI), such as infections, diarrhea, colitis, neutropenia, cutaneous reactions, ALT/AST elevation, and pneumonitis, were moderate and manageable with early intervention and dose modification.
Original languageEnglish
Pages (from-to)S20-S21
Number of pages2
JournalAMERICAN JOURNAL OF HEMATOLOGY
Volume94
Issue numberS2
DOIs
Publication statusPublished - Nov 2019
Event2019 Lymphoma and Myeloma Congress - Sheraton New York Times Square Hotel, New York, United States
Duration: 23 Oct 201926 Oct 2019

Keywords

  • Duvelisib
  • relapsed CLL/SLL
  • refractory CLL/SLL
  • PI3K
  • lymphoma

Fingerprint

Dive into the research topics of 'Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial'. Together they form a unique fingerprint.

Cite this